• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Étude BRIGALK.. Congrès de pneumologie de langue française, Jan 2019, Marseille, France. ⟨10.1016/j.rmr.2018.10.039⟩. ⟨hal-02633916⟩
• 
  Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, et al.. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer, 2019, 136, pp.109-114. ⟨10.1016/j.lungcan.2019.08.010⟩. ⟨hal-04529929⟩
• 
  Pauline Parent, Gautier Marcq, Sola Adeleke, Anthony Turpin, Stergios Boussios, et al.. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer. Therapeutic Advances in Medical Oncology, 2023, 15, pp.17588359231192402. ⟨10.1177/17588359231192402⟩. ⟨inserm-04521181⟩
• 
  Thibault Butel, Marie Karanian, Gaelle Pierron, Daniel Orbach, Dominique Ranchere, et al.. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. Cancer Medicine, 2020, 9 (8), pp.2698-2709. ⟨10.1002/cam4.2713⟩. ⟨hal-03882476⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Cécile Thomas-Teinturier, Rodrigue Sétchéou Allodji, Ekaterina Svetlova, Marie-Alix Frey, Odile Oberlin, et al.. Ovarian reserve after treatment with alkylating agents during childhood. Human Reproduction, 2015, 30 (6), pp.1437 - 1446. ⟨10.1093/humrep/dev060⟩. ⟨inserm-04439971⟩
• 
  Rodrigue S Allodji, Margaret A Tucker, Michael M Hawkins, Marie‐cécile Le Deley, Cristina Veres, et al.. Role of radiotherapy and chemotherapy in the risk of leukemia after childhood cancer: An international pooled analysis. International Journal of Cancer, 2020, 148 (9), pp.2079 - 2089. ⟨10.1002/ijc.33361⟩. ⟨inserm-04439010⟩
• 
  Grégory Delpon, Alexandre Escande, Timothée Ruef, Julien Darréon, Jimmy Fontaine, et al.. Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy. Frontiers in Oncology, 2016, 6, ⟨10.3389/fonc.2016.00178⟩. ⟨hal-01683878⟩
• 
  Arthur Petat, Eric Dansin, Fabien Calcagno, Laurent Greillier, Eric Pichon, et al.. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. European Journal of Cancer, 2022, 162, pp.118-127. ⟨10.1016/j.ejca.2021.11.028⟩. ⟨hal-03524368⟩
• 
  Maxime Enault, Véronique Minard-Colin, Nadège Corradini, Guy Leverger, Estelle Thebaud, et al.. Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, pp.64-78. ⟨10.1016/j.ejca.2021.10.025⟩. ⟨hal-04027205⟩
• 
  Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, et al.. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩. ⟨hal-03469622⟩
• 
  Othman Aissaoui, Jerome Phalippou, Abel Cordoba, Henri Azaïs, Lobna Ouldamer, et al.. Brachytherapy and surgery versus surgery alone for IB2 (FIGO 2018) cervical cancers: A FRANCOGYN study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2023, 290, pp.128-134. ⟨10.1016/j.ejogrb.2023.09.021⟩. ⟨hal-04336219⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Robin Coppin, Hélène Martelli, Cyrus Chargari, Hélène Sudour-Bonnange, Daniel H. Orbach, et al.. Outcome and late effects of patients treated for childhood vaginal malignant germ cell tumors. Pediatric Blood and Cancer, 2023, 70 (12), ⟨10.1002/pbc.30697⟩. ⟨hal-04271278⟩
• 
  Anne-Sophie Baudry, Laurence Vanlemmens, Anne Congard, Aurélie Untas, Carine Segura-Djezzar, et al.. Emotional processes in partners’ quality of life at various stages of breast cancer pathway: A longitudinal study. Quality of Life Research, 2022, ⟨10.1007/s11136-022-03298-6⟩. ⟨hal-03991505⟩
• 
  Anne‐sophie Baudry, Sonya Yakimova, Anne Congard, Aurélie Untas, Séverine Guiu, et al.. Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. Psycho-Oncology, 2022, 31 (5), pp.848-855. ⟨10.1002/pon.5876⟩. ⟨hal-03771024⟩
• 
  Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, et al.. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales). European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩. ⟨hal-04242387⟩

158

226